Comparative Pharmacology
Head-to-head clinical analysis: LYUMJEV versus SYNJARDY XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LYUMJEV versus SYNJARDY XR.
LYUMJEV vs SYNJARDY XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LYUMJEV (insulin lispro-aabc) is a rapid-acting insulin analog that binds to the insulin receptor (IR), activating the IR tyrosine kinase cascade. This leads to increased glucose uptake in peripheral tissues (primarily skeletal muscle and adipose tissue), inhibition of hepatic gluconeogenesis, and promotion of glycogen synthesis. The aabc amino acid substitution (insulin lispro with proline at B28 replaced by lysine and lysine at B29 replaced by proline, plus an additional modification) results in faster dissociation from the insulin receptor and accelerated absorption from subcutaneous tissue compared to regular human insulin.
Synjardy XR is a combination of empagliflozin, an SGLT2 inhibitor that reduces renal glucose reabsorption, and metformin, an AMPK activator that decreases hepatic glucose production and improves insulin sensitivity.
Subcutaneous injection at mealtime (within 15 minutes before or immediately after meal). Doses individualized; typical range 0.2-1.0 units/kg/day.
Initial dose: 5 mg empagliflozin/500 mg metformin extended-release orally twice daily with meals. Titrate based on glycemic control and tolerability up to maximum 25 mg empagliflozin/1000 mg metformin XR twice daily.
None Documented
None Documented
Terminal elimination half-life of LYUMJEV (insulin lispro) is approximately 13.7 minutes (0.23 hours) in healthy subjects, reflecting rapid clearance from the bloodstream.
Empagliflozin: Terminal half-life ~12.4 hours (supports once-daily dosing). Metformin: Terminal half-life ~6.2 hours (plasma); elimination half-life prolonged in renal impairment (up to 17.6 hours in patients with reduced GFR).
Primarily renal; approximately 90% of absorbed dose is excreted via urine as metabolites and unchanged drug, with the remainder eliminated in feces (<10%).
Empagliflozin: Approximately 54% excreted unchanged in urine, 41% in feces (metabolites). Metformin: ~90% excreted unchanged in urine via tubular secretion and glomerular filtration; renal clearance ~510 mL/min.
Category C
Category C
Antidiabetic
Antidiabetic